Clinical-stage biotechnology company Wave Life Sciences Ltd. (WVE) continues to build momentum across its RNA editing and silencing programs, with multiple clinical and preclinical milestones expected before the end of 2025.
The company's pipeline is anchored by WVE-006, a GalNAc-conjugated A-to-I RNA editing oligonucleotide being evaluated in the Phase 1b/2a RestorAATion-2 study for alpha-1 antitrypsin deficiency (AATD).
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.